<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Bradley Corr, MD, on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer

by OncLive | May 10, 2024
placeholder

Bradley R. Corr, MD, explores the rationale and results of a phase 2 trial comparing rucaparib to placebo as maintenance therapy for metastatic and recurrent endometrial cancer. Discover the significant progression-free survival improvements and implications for patients in this insightful discussion.

Topics: Press Coverage

Comments